Cempra reports positive trial data but stoc

Cempra Inc. (Nasdaq: CEMP) reported positive data from a Phase 3 clinical trial of intravenous to oral solithromycin to treat patients with community-acquired bacterial pneumonia but the stock price plunged $7.88 to $18.90.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.